Compare Mesoblast Limited (MESO) vs Twilio Inc (TWLO) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Twilio (TWLO) trades at $250.06, up 3.64% with strong technical momentum and bullish moving average signals. The stock has delivered three consecutive earnings beats, with Q2 2026 EPS of $1.47 beating expectations by 11%. Revenue growth accelerated to 22% year-over-year in Q2, prompting management to raise full-year guidance to 18-18.5% growth. The company achieved record free cash flow generation with margins improving significantly.

Twilio presents compelling growth prospects with accelerating revenue and robust cash flow generation. However, elevated valuation multiples (P/E 35.35, EV/EBITDA 75.54) and overbought technical indicators suggest near-term consolidation risk. Analyst consensus remains strongly bullish with 77% buy ratings and $266.31 price target, representing 6.5% upside from current levels.